Add like
Add dislike
Add to saved papers

Effects of encapsulated organic acids and essential oils on intestinal barrier, microbial count, and bacterial metabolites in broiler chickens.

Poultry Science 2019 January 32
The aim of this study was to evaluate a combination diet of organic acids and essential oils on epithelial restitution, intestinal microflora, and volatile fatty acids in broiler chickens. A total of 144 1-day-old male chicks (Cobb 500) were allotted to 3 treatment groups consisting of 6 replicates with 8 birds per replicate. The dietary treatments were as follows: control group (CON, basal diet), antibiotics group (ANT, control + 0.15 g/kg enramycin), and addition group (EOA, control + 0.30 g/kg encapsulated organic acids and essential oils). Compared to the CON group, the EOA group showed a higher feed conversion ratio (FCR) (P < 0.05) at day 42. The ANT group showed the lowest count of Lactobacillus spp. (P < 0.05) and the highest count of Escherichia coli (P < 0.05) in the ileal digesta. Birds that were fed the EOA-supplemented diet had decreased populations of E. coli (P < 0.05). Compared with the ANT group, supplementation with EOA tended to reduce the pH of jejunal digesta (P = 0.079) and ileal digesta (P = 0.078) but significantly increased the concentration of butyric acid (P < 0.05) and tended to increase the concentrations of acetic acid (P = 0.087) and total short-chain fatty acids (SCFA; P = 0.098) in the ileal digesta. The EOA group showed higher sucrase and maltase activities of jejunal mucosa (P < 0.05) than those in the other groups. The EOA supplementation increased (P < 0.05) claudin-1 mRNA expression in the jejunum. Compared with the other groups, enramycin supplementation significantly reduced jejunal mucosa sIgA (P < 0.05) and down-regulated Mucin-2 and TLR2 mRNA relative expression (P < 0.05) in the jejunal mucosa of broiler chickens. Both EOA and enramycin contribute beneficially to FCR because of their antimicrobial action. EOA may reduce harmful bacteria and promote digestive enzyme activity and higher concentrations of SCFA. In contrast, enramycin may inhibit the growth of beneficial bacteria and reduce the need for intestinal mucosal barrier function.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app